Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon

Arthritis and Rheumatism

Volumn 40, Issue 2, 1997, Pages 352-357

  Khan, Faisel ^a   Litchfield, Stuart J ^a   McLaren, Margaret ^a   Veale, Douglas J ^a   Littleford, Roberta C ^a   Belch, Jill J F ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ARGININE; NITROPRUSSIDE SODIUM; PLACEBO; VASODILATOR AGENT;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; FINGER; HUMAN; IONTOPHORESIS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SKIN BLOOD VESSEL; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; ADMINISTRATION, ORAL; ADULT; ARGININE; DOUBLE-BLIND METHOD; DRUG TOLERANCE; ERYTHROCYTES; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; NITROPRUSSIDE; PATIENT COMPLIANCE; PLACEBOS; RAYNAUD DISEASE; SKIN; VASODILATION; VASODILATOR AGENTS;

EID: 0031055696     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400220     Document Type: Article

References (15)

1. Belch JJF: Raynaud's phenomenon. Curr Opin Rheumatol 1:490-498, 1989
2. Khan F, Coffman JD: Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon. Circulation 89:1183-1188, 1994
3. Bedarida GV, Kim D, Blaschke TF, Hoffman BB: Venodilation in Raynaud's disease. Lancet 342:1451-1454, 1993
4. Belch JJF, Zoma A, Richards I, Forbes CD, Sturrock RD: Vascular damage and factor VIII related antigen in the rheumatic disease. Rheumatol Int 7:107-111, 1987
5. Agostoni A, Marasini B, Biondi ML, Bassani C, Cazzaniga A, Bottasso B, Cugno M: L-arginine therapy in Raynaud's phenomenon. Int J Clin Lab Res 21:202-203, 1991
6. Vallance P, Collier J, Moncada S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 2:997-1000, 1989
7. Khan F, Davidson NC, Littleford RC, Struthers AD, Belch JJF: Vasodilation to acetylcholine is mediated by a prostacyclin- dependent mechanism in human forearm skin (abstract). Circulation 92:1-429, 1995
8. Rubanyi GM, McKinney M, Vanhoutte PM: Biphasic release of endothelium-derived relaxing factor(s) by acetylcholine from perfused canine femoral arteries: characterization of muscarinic receptors. J Pharmacol Exp Ther 240:802-808, 1987
9. Kharitonov SA, Lubec G, Lubec B, Hjelm M, Barnes P: L-arginine increases exhaled nitric oxide in normal human subjects. Clin Sci 88:135-139, 1995
10. Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS: Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol 26:1054-1061, 1995
11. MacAllister RJ, Calver AL, Collier J, Edwards CMB, Herreros B, Nussey SS, Vallance P: Vascular and hormonal responses to arginine: provision of substrate for nitric oxide or non-specific effect? Clin Sci 89:183-190, 1995
12. Bode-Böger SM, B̈ger RH, Creutzig A, Tsikas D, Gutzi FM, Alexander K, Frölich JC: L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci 87:303-310, 1994
13. Reyes AA, Karl IE, Klahr S: Role of arginine in health and renal disease. Am J Physiol 267:F331-F346, 1994
14. Lau CS, Bridges A, Muir A, Scott N, Bancroft A, Belch JJF: Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon. Br J Rheumatol 31:375-380, 1992
15. 2 receptor hypersensitivity in Raynaud's phenomenon. J Vase Med Biol 2:100-106, 1990